The Mycoplasma Testing Market is gaining momentum as the biopharmaceutical industry expands its use of cell-based manufacturing and advanced therapies. The market is projected to increase from USD 1.21 billion in 2025 to USD 3.52 billion by 2035, representing a CAGR of 10.20% over the forecast period.

Rapid mycoplasma PCR testing is reshaping laboratory workflows by providing results substantially faster than conventional culture-based detection. Quantitative PCR remains the most widely used molecular approach, while digital PCR is gaining attention for applications that require high sensitivity and absolute quantification in low-biomass samples.

Gene and cell therapy manufacturing represents an important future application. As advanced therapies move from clinical development into commercial production, manufacturers need reliable contamination screening throughout cell banking, manufacturing, and product-release processes. This is expected to create additional demand for validated testing platforms and specialized services.

North America currently dominates the market, while Europe remains an important hub for biologics production and contract manufacturing. Asia-Pacific is developing rapidly, with a projected 16.50% CAGR, supported by new biomanufacturing facilities and expanding pharmaceutical capabilities in China and India.

Looking ahead, testing providers are likely to focus on automation, multiplex detection, digital PCR, and point-of-manufacturing solutions. Combining mycoplasma testing with broader microbial contamination workflows could help manufacturers reduce testing complexity while maintaining stringent quality standards.

Discover emerging opportunities with in-depth research reports:

Germanium68 Gallium68 Generator Market Size

Germanium68 Gallium68 Generator Market Share

Germanium68 Gallium68 Generator Market Trends

Germanium68 Gallium68 Generator Market Growth

Germanium68 Gallium68 Generator Market Demand